

1 **Discontinuity of care and trust in usual physician among patients with systemic lupus**
2 **erythematosus**

3 Yu Katayama MD, PhD¹; Yoshia Miyawaki MD, MPH, PhD¹; Kenta Shidahara MD¹; Shoichi
4 Nawachi MD¹; Yosuke Asano MD, PhD¹; Eri Katsuyama MD, PhD¹; Takayuki Katsuyama MD,
5 PhD¹; Mariko Takano-Narazaki MD, PhD¹; Yoshinori Matsumoto MD, PhD¹; Nao Oguro MD,
6 PhD²; Nobuyuki Yajima MD, MPH, PhD^{2, 3, 4}; Yuichi Ishikawa MD^{5, 6}; Natsuki Sakurai MD⁷;
7 Chiharu Hidekawa MD⁷; Ryusuke Yoshimi MD, PhD^{7, 8}; Shigeru Ohno MD, PhD⁹; Takanori
8 Ichikawa MD PhD¹⁰; Dai Kishida MD, PhD¹⁰; Yasuhiro Shimojima MD, PhD¹⁰; Ken-ei Sada
9 MD, PhD^{1, 11}; Jun Wada MD, PhD¹; David H Thom MD, PhD¹²; Noriaki Kurita MD, PhD^{13, 14}

10

- 11 1. Department of Nephrology, Rheumatology, Endocrinology, and Metabolism, Okayama
12 University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences,
13 Okayama, Japan
- 14 2. Division of Rheumatology, Department of Medicine, Showa University School of
15 Medicine, Tokyo, Japan
- 16 3. Center for Innovative Research for Communities and Clinical Excellence, Fukushima
17 Medical University, Fukushima, Japan
- 18 4. Department of Healthcare Epidemiology, School of Public Health in the Graduate School
19 of Medicine, Kyoto University, Kyoto, Japan
- 20 5. The First Department of Internal Medicine, School of Medicine, University of
21 Occupational and Environmental Health, Kitakyushu, Japan
- 22 6. Graduate School of Health Innovation, Kanagawa University of Human Services,
23 Kawasaki, Kanagawa, Japan

- 24 7. Department of Stem Cell and Immune Regulation, Yokohama City University Graduate
25 School of Medicine, Yokohama, Japan
- 26 8. Clinical Laboratory Department, Yokohama City University Hospital, Yokohama, Japan
- 27 9. Center for Rheumatic Disease, Yokohama City University Medical Center, Yokohama,
28 Japan
- 29 10. Department of Medicine (Neurology and Rheumatology), Shinshu University School of
30 Medicine, Matsumoto, Japan
- 31 11. Department of Clinical Epidemiology, Kochi Medical School, Nankoku, Japan
- 32 12. Department of Medicine, Stanford University School of Medicine, Palo Alto, California,
33 USA
- 34 13. Department of Clinical Epidemiology, Graduate School of Medicine, Fukushima Medical
35 University, Fukushima, Japan
- 36 14. Department of Innovative Research and Education for Clinicians and Trainees (DiRECT),
37 Fukushima Medical University Hospital, Fukushima, Japan

38

39 **Corresponding Author:** Yoshia Miyawaki, MD, MPH, PhD, Department of Nephrology,
40 Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of
41 Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-
42 8558, Japan.

43 E-mail: pebe1a85@okayama-u.ac.jp

44

45 Word counts: 2279 words

46

47

48 **Key Points**

49 **Question** Is the number of outpatient visits with a covering rheumatologist associated with the
50 loss of trust in usual rheumatologist in patients with systemic lupus erythematosus (SLE)?

51 **Findings** This multicenter cross-sectional study which included 421 patients with SLE revealed
52 that the number of outpatient visits with a covering rheumatologist in the past year was
53 associated with lower levels of trust in the usual rheumatologist.

54 **Meaning** This study alerts us about the need to prepare for the possible adverse effects of
55 unavoidable outpatient coverage.

56

57

58 **Abstract**

59 **Importance:**

60 Patient trust plays a central role in the patient-physician relationship; however, the impact of
61 outpatient visits with a covering physician (covered visits) on the level of trust in usual physician
62 among patients with chronic conditions is unknown.

63

64 **Objective:**

65 To determine whether the number of outpatient visits with a covering rheumatologist is
66 associated with patient trust in the usual rheumatologist.

67

68 **Design:**

69 Cross-sectional study.

70

71 **Setting:**

72 This study used data from the TRUMP²-SLE project conducted at five academic medical centers
73 in Japan.

74

75 **Participants:**

76 The participants were Japanese adults with systemic lupus erythematosus who met the 1997
77 revised classification criteria of the American College of Rheumatology.

78 The enrollment period was February 2020 to October 2021.

79

80 **Exposure:**

81 Outpatient visits with a covering rheumatologist in the past year.

82

83 **Main Outcomes and Measures:**

84 The main outcome was patient trust in their usual rheumatologist, assessed using the 11-item
85 Japanese version of the modified Trust in Physician Scale (range 0–100). A general linear model
86 with cluster robust variance estimation was used to evaluate the association between the number
87 of outpatient visits with a covering rheumatologist and the patient's trust in their usual
88 rheumatologist.

89

90 **Results:**

91 Of the 515 enrolled participants, 421 patients with systemic lupus erythematosus were included
92 in our analyses.

93 The median age was 47.0 years, and 87.2% were women. Thirty-nine usual rheumatologists
94 participated in this study. Patients were divided into groups according to the number of

95 outpatient visits with a covering rheumatologist in the past year as follows: no visits (59.9%;
96 reference group), one to three visits (24.2%; low-frequency group), and four or more visits
97 (15.9%; high-frequency group). The median Trust in Physician Scale score was 81.8
98 (interquartile range 72.7–93.2). Both the low-frequency and high-frequency groups exhibited
99 lower trust in their usual rheumatologist (mean difference: -3.03 [95% confidence interval -5.93
100 to -0.80], -4.17 [95% confidence interval -7.77 to -0.58, respectively]).

101

102 **Conclusions and Relevance:**

103 This study revealed that the number of outpatient visits with a covering rheumatologist was
104 associated with lower trust in a patient's usual rheumatologist. Further research is needed to
105 address the potential adverse effects of physician coverage on trust in patient's usual
106 rheumatologist.

107

108

109 **Introduction**

110 Discontinuity of care is a critical process with the potential to adversely affect the quality of
111 patient care. For example, discontinuity of care has been associated with more avoidable
112 hospitalizations and a higher number of procedures.^{1,2} While significant attention has been
113 directed toward inpatient handovers³ and transitions related to year-end resident changeovers,^{4,5}
114 the impact of temporary outpatient physician coverage remains an understudied clinical question.
115 The necessity for coverage of outpatient care, in the absence of the usual physician is a common
116 and unavoidable occurrence,⁶ due to factors such as continuing medical education, maternity
117 leave, or unexpected absenteeism caused by illness.⁷ Acting as a surrogate during the usual
118 physician's absence,⁸ the covering physician assumes identical responsibilities to those of the
119 primary physician.⁹

120 Systemic lupus erythematosus (SLE), characterized by multiple organ damage, requires life-long
121 outpatient visits to mitigate functional disability and optimize quality of life. Maintaining a good
122 physician-patient therapeutic relationship is important because outpatient rheumatologists are
123 required to evaluate patients with SLE through laboratory testing and adjust complex
124 medications based on changes in their disease activity. Trust in the primary rheumatologist is
125 central to this therapeutic relationship,¹⁰ and among patients with SLE, trust is associated with
126 excellent medication adherence.¹¹

127 When a patient's visit requires coverage by another rheumatologist, the covering rheumatologist
128 is expected to maintain the same quality of care. However, the course of SLE may not be static,
129 and the covering rheumatologist may be forced to make decisions about prescriptions and testing
130 in the absence of an established relationship with the patient.¹² When a patient with SLE
131 experiences an unsatisfactory visit with a covering rheumatologist, it may erode their trust in
132 their primary rheumatologist. However, although the association between trust and discontinuity

133 of care has been examined primarily in European and US primary care settings, the results from
134 quantitative studies have been mixed,^{13 14} and few studies have focused on the discontinuity
135 associated with outpatient physician coverage within the same department.
136 The aim of this study was to examine the association between the number of outpatient
137 rheumatologist coverage by colleagues within the same department and patient trust in the
138 primary rheumatologist among Japanese patients with SLE using data from the Trust
139 Measurement for Physicians and Patients with SLE (TRUMP²-SLE) project, a multicenter cross-
140 sectional study.

141

142 **Methods**

143 *Study design and subjects*

144 This was a cross-sectional study using baseline data from the TRUMP²-SLE study, a multicenter
145 cohort study currently conducted at five academic medical centers (Showa University Hospital,
146 Okayama University Hospital, Shinshu University Hospital, Yokohama City University Hospital,
147 Yokohama City University Medical Center). Patients ≥ 20 years old who met the revised criteria
148 in 1997 for the classification of SLE by the American College of Rheumatology (ACR) were
149 included.¹⁵ Patients who were seen by their usual rheumatologist for the first time were excluded.
150 All patients provided informed consent prior to enrollment. The patients were consecutively
151 recruited between February 2020 and October 2021.

152

153 *Exposure*

154 Exposure in the present study was defined as the patient-reported number of outpatient visits by
155 a covering rheumatologist (NVCs) in the past year. A covering rheumatologist was defined as
156 one in the same facility other than the usual rheumatologist. Based on frequency, the NVCs were

157 classified into three categories: (1) no NVCs (2) one to three NVC (low-frequency group), and
158 (3) four or more NVCs (high-frequency group).

159

160 *Outcome*

161 The outcome of this study was trust in patients' usual rheumatologist, using the Japanese version
162 of the 11-item modified Trust in Physicians Scale by Thom.^{10,16} Each item is rated on a 5-point
163 Likert scale ranging from 1 (totally disagree) to 5 (totally agree). Then, the four negatively
164 worded items were reverse coded and the total score of all items was converted to a range of 0 to
165 100. This scale has demonstrated high internal consistency reliability (Cronbach's alpha
166 coefficient = 0.91) and criterion-related validity.¹⁰

167

168 *Covariates*

169 Based on previous literature and the clinical expertise of rheumatologists, the potential
170 confounders were determined to be as follows: patient age,¹⁷ patient sex,¹⁷ physician age,¹⁸
171 physician sex,¹⁸ job title,¹⁹ duration of time since diagnosis of SLE,¹⁹ disease activity, organ
172 damage, emotional health, the duration of the relationship with their usual rheumatologist
173 (categorized as <1 year, 1-3 years, and 3 years or more) and the number of visits to their usual
174 rheumatologist in the past year (categorized as one to three times, four to six times, and seven
175 times or more).^{10,18} As there are only full professor and associate professor job titles in Japan that
176 contains the Kanji character 'kyouju', meaning professor in English, and health information from
177 an authority is more likely to be trusted, the job titles were divided into two groups: associate
178 professor or higher and lecturer or lower.¹⁹ Disease activity was determined by the usual
179 physician using the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K).
180 Organ damage was determined by the Systemic Lupus Erythematosus International Cooperative

181 Clinic/American College of Rheumatology Disability Index (SDI). Emotional health was
182 determined by the LupusPRO domain and was converted to a 0–100-point score.²⁰ Higher
183 emotional health scores indicated better emotional functioning and role emotional.

184

185 *Statistical analysis*

186 Patient characteristics were summarized separately by NVCs with continuous variables as
187 median and interquartile range (IQR) and categorical variables as frequencies and percentages. A
188 general linear model was fit to examine the association between NVCs and the trust in the usual
189 rheumatologist. All the above-mentioned covariates were entered into the model. In addition, to
190 examine the possibility that the duration of the relationship with their usual physician may
191 modify the association between NVCs and trust in the physician, their product terms were
192 entered into the model. The presence of the interaction was assessed using the Wald test. Next, a
193 logistic regression model was fit with all the above-mentioned covariates as explanatory
194 variables to explore factors associated with high-frequency NVCs. In both of the models, cluster-
195 robust variance estimation was used with each usual rheumatologist as a cluster unit to address
196 the possibility of outcome similarity (i.e., clustering) for the same usual rheumatologist.²¹
197 Multiple imputation with chained equations was used to address missing data, assuming that the
198 data were missing at random.²² All missing values were multiply-imputed 100 times in the
199 imputation process. These estimates were combined using Rubin's rule.²² All analyses were
200 performed using Stata software (version 17.0; Stata Corp, College Station, TX, USA). Statistical
201 significance was set at $p < 0.05$.

202

203 *Ethical considerations*

204 This study was conducted in accordance with the Declaration of Helsinki, and the study protocol
205 was approved by the Graduate School of Medical and Dental Sciences of Okayama University
206 and the Okayama University Hospital Ethics Committee (approval number: 2204-020).

207

208 **Results**

209 *Patient and physician characteristics*

210 Of the 515 patients enrolled, 94 were excluded owing to missing or inadequate data on outcomes
211 and exposures, and 421 were ultimately included in the primary analysis. The participant and
212 physician characteristics are shown in Table 1. The median age of the patients was 47 years (IQR
213 36–57), and 367 (87.2%) were female. The median duration of the disease was 12.6 years (IQR
214 6.9–20.3), the median SLEDAI-2K score was 4 (IQR 1–6), and the median SDI was 0 (IQR 0–1).
215 Regarding NVCs, 252 (59.9%) had no visits, 102 (24.2%) had low frequency (1-3 visits), and 67
216 (15.9%) had high frequency (≥ 4 visits). Patients were seen by a total of 39 usual rheumatologists.
217 The median age of the rheumatologists was 43 years (IQR 38–48), and nine (23.1%) were female.
218 Seven (17.9%) rheumatologists were associate professors or higher in job titles.

219

220 *Association between NVCs and trust in one's usual physician*

221 The median Trust in Physician Scale score was 81.8 (IQR 72.7–93.2) and the mean was 81.6
222 (standard deviation 13.3). The distribution of Trust in Physician Scale Score is shown in Figure 1.
223 The association between NVCs and trust in the patient's usual physician is shown in Table 2. In
224 the adjusted model, compared to no NVCs, both low and high frequency NVCs were associated
225 with lower Trust in Physician Scale scores, respectively (adjusted mean difference: -3.01 [95%
226 confidence interval (CI) -5.93 to -0.80] and -4.17 [95% CI -7.77 to -0.58], respectively). We
227 failed to demonstrate evidence of a global interaction between the association between NVCs

228 and Trust by duration of the relationship with the usual rheumatologist and NVCs (*P* for
229 interaction = 0.138).

230

231

232 *Factors associated with high frequent NVCs*

233 The exploratory associations between high-frequency NVCs and covariates are shown in Table 3.

234 Greater organ damage (per 1 point higher SDI: aOR 1.27, 95%CI 1.06–1.52) and more frequent

235 visits to the usual physician (one to three times vs. four to six times: aOR 3.94, 95%CI 1.48–

236 10.48 / one to three times vs. seven or more times: aOR 3.86, 95%CI 1.46–10.16) was positively

237 associated with a high frequency of NVCs. On the other hand, better emotional health (per point

238 higher: aOR 0.98, 95%CI 0.97–0.99) and higher disease activity (per 1 point higher SLEDAI-

239 2K: aOR 0.90, 95%CI 0.84–0.97) were inversely associated with a high frequency of NVCs.

240

241 **Discussion**

242 The present study showed that more frequent NVCs with a covering rheumatologist were

243 associated with trust in the usual rheumatologist among patients with SLE. The study found a

244 higher frequency of NVCs was associated with greater organ damage, lower emotional health,

245 and greater number of visits to the usual rheumatologist in the past year.

246 Few studies have investigated the effects of outpatient visits with a covering physician on the

247 patient relationship with their usual physician among patients with a chronic disease. However,

248 some studies have helped us to understand the findings of our study. First, rheumatologists can

249 understand the possible mechanisms of the loss of trust with increased NVCs by revisiting the

250 level of trust in their physicians. For example, if the usual rheumatologist's planned care (e.g.,

251 performing laboratory tests and explaining their results, or changing the dosage or class of

252 medications) is not communicated to a covering rheumatologist, the patient may feel that the
253 rheumatologists' words and actions are not credible.²³ On the other hand, a covering
254 rheumatologist may be hesitant to change medications or order additional testing, preferring to
255 defer to the patient's usual rheumatologist, which could result in a delayed response to changes
256 in the patient with SLE. In addition, if changes in care are not communicated clearly to the usual
257 rheumatologist, the patient may feel the usual rheumatologist is less informed and therefore less
258 capable of providing the best care. The finding that patients with lower emotional health due to
259 depression and/or anxiety are due to those patients requesting visits more urgently than can be
260 scheduled with their usual rheumatologist.

261 The clinical implications of this study are noteworthy. First, rheumatologists need to be aware of
262 the magnitude and meanings of frequent NVCs on the patients' trust in their usual
263 rheumatologists. The magnitude of the 4.17-point lowering of trust scores associated with high
264 frequency (≥ 4 times/year) NVCs is equivalent to the magnitude (4.30 points) of the impact of
265 past misdiagnosis experiences on trust lowering in the current usual physicians.¹⁰ Second,
266 rheumatologists need to establish preventive measures against loss of trust resulting from
267 physician coverage. For example, as in the case of computerized tools,²⁴ medical facilities would
268 be encouraged to implement a semi-automatic system for handovers of planned laboratory
269 testing, patient explanations, and prescriptions to a covering physician. Alternatively, they could
270 also consider operating an electronic record or a card to be shared whenever any change in
271 patient care occur.⁶ More fundamentally, a system that prevents physician coverage would be
272 ideal. For example, if a rheumatologist takes a day off in advance, a patient scheduled to visit on
273 that day should be notified beforehand to change their appointment date or accept an
274 examination by a covering rheumatologist, thereby avoiding patient surprise or disappointment
275 when they enter an examination room and meets an unfamiliar physician.

276 This study had several strengths worth mentioning. First, this was a multicenter study; Therefore,
277 the observed effects of rheumatologists' NVCs on patients' trust are generalizable to similar
278 academic medical centers, instead of reflecting the specific medical structure of a particular
279 institution's department. Second, we adjusted for the physician-level clustering of trust with
280 appropriate multilevel analyses by merging data both from usual rheumatologists and from a
281 large number of their patients.²¹ As a result, the observed association between rheumatologists'
282 NVCs and trust was not reflective of a particular rheumatologist's behavior.¹⁹ Third, the
283 racial/ethnic homogeneity means that race/ethnicity is not a complicating factor.²⁵
284 Several limitations should be noticed in this study. First, the possibility of reverse causation
285 cannot be excluded because of the cross-sectional study design. Some patients may have asked to
286 see a covering rheumatologist because they had less trust in their usual rheumatologist. Second,
287 we were unable to survey the reasons for the physician coverage. In addition to the usual
288 rheumatologist's reasons for arranging coverage, patients may have visited another
289 rheumatologist on a day other than the day of their appointments for patient-related reasons. For
290 example, patients may have rescheduled their appointments on a day when their rheumatologists
291 were not available, or they may have visited another rheumatologist because of unexpected
292 illness. Third, the generalizability of the findings of this study, which were conducted at
293 academic medical centers affiliated with many rheumatologists, may be limited. For example, in
294 the rheumatology departments of city hospitals or private clinics, where only one rheumatologist
295 is often affiliated, rheumatologists must rely on non-rheumatology colleagues or locum tenens
296 for their coverage.^{7 26}
297 In conclusion, frequent outpatient NVCs by a covering rheumatologist were associated with a
298 lower trust in the using rheumatologist among patients with SLE. Given that occasional time off

299 is sometimes required to sustain a medical practice without burnout, this study alerts us about the

300 need to prepare for possible adverse effects of unavoidable outpatient coverage.

301

302 **Acknowledgment**

303 **Author Contributions:** Dr Katayama and Kurita had full access to all of the data in the study
304 and take responsibility for the integrity of the data and the accuracy of the data analysis.

305 *Concept and design:* Katayama, Miyawaki, Kurita.

306 *Acquisition, analysis, or interpretation of data:* All authors.

307 *Drafting of the manuscript:* Katayama, Miyawaki, Kurita.

308 *Critical revision of the manuscript for important intellectual content:* All authors. *Statistical*
309 *analysis:* Katayama, Miyawaki, Kurita.

310 *Obtained funding:* Y.Matsumoto, Kurita

311 *Administrative, technical, or material support:* Katayama, Miyawaki, Yajima, Yoshimi,
312 Shimojima, Sada, Kurita.

313 *Supervision:* Miyawaki, Yajima, Yoshimi, Shimojima, Sada, Thom, Kurita.

314 **Conflict of Interest Disclosures:** Dr Kurita reported receiving grants from the Japan Society for
315 the Promotion of Science, consulting fees from GlaxoSmithKline K.K., and payments for
316 speaking at and participating in educational events from Chugai Pharmaceutical Co, Ltd, Sanofi
317 K.K., Mitsubishi Tanabe Pharma Corporation, and the Japan College of Rheumatology. Dr Sada
318 reported receiving a research grant from Pfizer Inc and a payment for speaking at and
319 participating in educational events from GlaxoSmithKline K.K. Dr Wada reported receiving
320 speaker honoraria from Astra Zeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Kyowa
321 Kirin, Novo Nordisk, and Mitsubishi Tanabe, and receives grant support from Bayer, Chugai,
322 Kyowa Kirin, Otsuka, Shionogi, Sumitomo, and Mitsubishi Tanabe. Dr Matsumoto reported
323 receiving grants from Asahi Kasei Pharma, Taisho and AbbVie, receives speaker honoraria from
324 Astra Zeneca, Asahi Kasei Pharma, GlaxoSmithKline and Pfizer and receives a payment for
325 participating in educational events from GlaxoSmithKline.

326 **Funding/Support:** This study was supported by JSPS KAKENHI Grant Numbers 19KT0021 (N.
327 K.) and 22K19690 (N. K.).

328 **Role of the Funder/Sponsor:** The funder had no role in the study design, analyses,
329 interpretation of the data, writing of the manuscript, or the decision to submit it for publication.

330 **Data Sharing Statement:** The dataset analyzed in this paper is available from the corresponding
331 author on reasonable request.

332 **Additional Contributions:** The authors are grateful to all collaborators in the TRUMP²-SLE
333 project.

334

335

336 **References**


- 337 1. Hussey PS, Schneider EC, Rudin RS, Fox DS, Lai J, Pollack CE. Continuity and the
338 costs of care for chronic disease. *JAMA Intern Med.* 2014;174(5):742-748.
- 339 2. Romano MJ, Segal JB, Pollack CE. The Association Between Continuity of Care and the
340 Overuse of Medical Procedures. *JAMA Intern Med.* 2015;175(7):1148-1154.
- 341 3. Horwitz LI, Moin T, Krumholz HM, Wang L, Bradley EH. Consequences of inadequate
342 sign-out for patient care. *Arch Intern Med.* 2008;168(16):1755-1760.
- 343 4. Young JQ, Ranji SR, Wachter RM, Lee CM, Niehaus B, Auerbach AD. "July effect":
344 impact of the academic year-end changeover on patient outcomes: a systematic review.
345 *Ann Intern Med.* 2011;155(5):309-315.
- 346 5. Young JQ, Wachter RM. Academic year-end transfers of outpatients from outgoing to
347 incoming residents: an unaddressed patient safety issue. *Jama.* 2009;302(12):1327-1329.
- 348 6. Anderson J, Kels BD, Grant-Kels JM. Ethical considerations in alleged dermatologic
349 malpractice. *Clin Dermatol.* 2012;30(2):174-180.

- 350 7. Maniscalco MM. A physician's guide to working as a locum tenens. *J Am Board Fam*
351 *Pract.* 2003;16(3):242-245.
- 352 8. Becker WG. The covering physician. *J Am Med Dir Assoc.* 2008;9(9):687-688.
- 353 9. McQuoid-Mason DJ. 'Covering doctors' standing in for unavailable colleagues: What is
354 the legal position? *S Afr Med J.* 2017;108(1):19-21.
- 355 10. Suzuki R, Yajima N, Sakurai K, et al. Association of Patients' Past Misdiagnosis
356 Experiences with Trust in Their Current Physician Among Japanese Adults. *J Gen Intern*
357 *Med.* 2022;37(5):1115-1121.
- 358 11. Kurita N, Oguro N, Miyawaki Y, et al. Trust in the attending rheumatologist, health-
359 related hope and medication adherence among Japanese systemic lupus erythematosus
360 patients. *Rheumatology (Oxford).* 2023;62(6):2147-2153.
- 361 12. Fulton J. Opioids, pain, and personality: the story of a substitute physician. *Can Fam*
362 *Physician.* 2011;57(3):271-272.
- 363 13. Mainous AG, 3rd, Baker R, Love MM, Gray DP, Gill JM. Continuity of care and trust in
364 one's physician: evidence from primary care in the United States and the United Kingdom.
365 *Fam Med.* 2001;33(1):22-27.
- 366 14. O'Malley AS, Sheppard VB, Schwartz M, Mandelblatt J. The role of trust in use of
367 preventive services among low-income African-American women. *Prev Med.*
368 2004;38(6):777-785.
- 369 15. Hochberg MC. Updating the American College of Rheumatology revised criteria for the
370 classification of systemic lupus erythematosus. *Arthritis Rheum.* 1997;40(9):1725.

- 371 16. Thom DH, Ribisl KM, Stewart AL, Luke DA. Further validation and reliability testing of
372 the Trust in Physician Scale. The Stanford Trust Study Physicians. *Med Care*.
373 1999;37(5):510-517.
- 374 17. Li C, Khan MM. Public trust in physicians: empirical analysis of patient-related factors
375 affecting trust in physicians in China. *BMC Prim Care*. 2022;23(1):217.
- 376 18. Fiscella K, Meldrum S, Franks P, et al. Patient trust: is it related to patient-centered
377 behavior of primary care physicians? *Med Care*. 2004;42(11):1049-1055.
- 378 19. Oguro N, Yajima N, Ishikawa Y, et al. Effect of Attending Rheumatologists' Big 5
379 Personality Traits on Patient Trust in Patients With Systemic Lupus Erythematosus: The
380 TRUMP2-SLE Project. *J Rheumatol*. 2024;51(2):168-175.
- 381 20. Inoue M, Shiozawa K, Yoshihara R, et al. The Japanese LupusPRO: A cross-cultural
382 validation of an outcome measure for lupus. *Lupus*. 2017;26(8):849-856.
- 383 21. Cameron AC, Miller DL. A practitioner's guide to cluster-robust inference. *Journal of*
384 *human resources*. 2015;50(2):317-372.
- 385 22. Austin PC, White IR, Lee DS, van Buuren S. Missing Data in Clinical Research: A
386 Tutorial on Multiple Imputation. *Can J Cardiol*. 2021;37(9):1322-1331.
- 387 23. Pearson SD, Raeke LH. Patients' trust in physicians: many theories, few measures, and
388 little data. *J Gen Intern Med*. 2000;15(7):509-513.
- 389 24. Flanagan ME, Patterson ES, Frankel RM, Doebbeling BN. Evaluation of a physician
390 informatics tool to improve patient handoffs. *J Am Med Inform Assoc*. 2009;16(4):509-
391 515.
- 392 25. Boulware LE, Cooper LA, Ratner LE, LaVeist TA, Powe NR. Race and trust in the
393 health care system. *Public Health Rep*. 2003;118(4):358-365.

- 394 26. Inoue K, Matsumoto M, Igarashi M. Short term locum tenens for rural practice: a trial of
395 a Japanese medical school. *Aust J Rural Health*. 2002;10(2):80-86.
396

397 **Figure 1.** The distribution of Trust in Physician Scale Score



398

399 The median Trust in Physician Scale score was 81.8 (IQR 72.7–93.2) and the mean was 81.6 (standard deviation 13.3).

400

401 **Table 1.** Patient and physician characteristics

Patient characteristics, n=421	Total	NVC			Missing, n
		0 N=252	1 to 3 N=102	4 or more N=67	
Patient age, median (IQR)	47.0 (36.0-57.0)	47.0 (36.0-59.0)	42.0 (34.8-50.0)	51.0 (41.0-63.0)	0
Patient sex, female n (%)	367 (87.2%)	218 (86.5%)	95 (93.1%)	54 (80.6%)	0
SLEDAI-2K score, median (IQR)	4.0 (1.0-6.0)	4.0 (2.0-6.0)	4.0 (2.0-6.0)	2.0 (0.0-6.0)	0
SDI score, median (IQR)	0.0 (0.0-1.0)	0.0 (0.0-1.0)	0.0 (0.0-1.0)	1.0 (0.0-2.0)	0
Disease duration, year, median (IQR)	12.6 (6.9-20.3)	12.6 (7.3-18.6)	9.3 (6.3-18.6)	17.5 (9.7-29.2)	5
Emotional health domain score, median (IQR)	79.2 (54.2-91.7)	79.2 (62.5-91.7)	79.2 (54.2-87.5)	66.7 (33.3-91.7)	63
Duration of rheumatologist- patient relationship, n (%)					12
< 1 year	69 (16.4)	36 (14.3%)	21 (20.6%)	12 (17.9%)	
1 to 3 years	76 (18.1%)	46 (18.3%)	15 (14.7%)	15 (22.4%)	
3 years or more	264 (62.7%)	163 (64.7%)	62 (60.8%)	39 (58.2%)	
Number of visits to usual rheumatologist, n (%)					9
1 to 3 times	52 (12.4%)	33 (13.1%)	15 (14.7%)	4 (6.0%)	
4 to 6 times	210 (49.9%)	132 (52.4%)	44 (43.1%)	34 (50.7%)	
7 times or more	150 (35.6%)	82 (32.5%)	41 (40.2%)	27 (40.3%)	

Rheumatologist characteristics, n=39	Total
Rheumatologist age, median (IQR)	43.0 (38.0-48.0)
Rheumatologist sex, female, n (%)	9 (23.1)
Job title, n (%)	
Lecturer or lower	32 (82.1)
Associated professor or higher	7 (17.9)

402 IQR; interquartile range NVC; Number of outpatient visits to covering rheumatologist

403 SLEDAI-2K; Systemic Lupus Erythematosus Disease Activity Index 2000

404 SDI; Systemic Lupus Erythematosus International Cooperative Clinic/ American College of Rheumatology Disability Index

405

406 **Table 2.** The association between NVCs and trust in one’s usual rheumatologist

The number of visits to covering rheumatologist	Crude		Adjusted	
	β coefficient [95%CI]	P-value	β coefficient [95%CI]	P-value
No visit	Reference		Reference	
1 to 3 visits	-2.53 [-5.51 to 0.45]	0.094	-3.01 [-5.93 to -0.80]	0.044
4 visits or more	-5.84 [-9.54 to -2.14]	0.003	-4.17 [-7.77 to -0.58]	0.024

407

408 NVC; Number of outpatient visits to a covering rheumatologist

409 General linear models with cluster-robust variance with usual rheumatologists as the unit were fit to address the clustering of
410 outcomes by the rheumatologists.

411 Adjusted models included patient age, sex, rheumatologist age, sex, job title, disease duration, SLEDAI, SDI, emotional health,
412 duration of rheumatologist-patient relationship, and number of visits to their usual rheumatologist

413

414 **Table 3.** Patient and usual rheumatologist factors associated with high frequent number (≥ 4 times/year) of outpatient visits covering

	Odds ratio (95%CI)	P-value
Patient age, per 1-yr higher	1.01 (0.99-1.02)	0.551
Patient sex, female vs male	0.55 (0.24-1.25)	0.153
Rheumatologist age, per 1-yr higher	1.03 (0.95-1.11)	0.512
Rheumatologist sex, female vs male	0.77 (0.24-2.48)	0.660
SLEDAI-2K, per 1-pt higher	0.90 (0.84-0.97)	0.004
SDI, per 1-pt higher	1.27 (1.06-1.52)	0.008
Disease duration, per 1-yr higher	1.03 (0.99-1.07)	0.081
Job title, associated professor or higher vs lecturer or lower	1.34 (0.71-2.53)	0.366
Emotional health, per 1-pt higher	0.98 (0.97-0.99)	0.004
Duration of rheumatologist-patient relationship		
< 1 year	Reference	
1 to 3 years	0.63 (0.19-2.04)	0.436
3 years or more	0.41 (0.15-1.11)	0.081
Number of visits to usual rheumatologist		
1 to 3 times	Reference	

	4 to 6 times	3.94 (1.48-10.48)	0.006
	7 times or more	3.86 (1.46-10.16)	0.006
415	NVC; Number of outpatient visits to covering rheumatologist	SLEDAI-2K; Systemic Lupus Erythematosus Disease Activity Index	
416	2000		
417	SDI; Systemic Lupus Erythematosus International Cooperative Clinic/ American College of Rheumatology Disability Index		
418	Logistic regression model with cluster-robust variance with their usual rheumatologists as the unit was fit to address the clustering of		
419	outcomes by the rheumatologists.		
420	All variables described in the table were entered into the model.		
421			